Shots:
- Nippon has exercised its exclusive US commercialization option for tadekinig alfa in Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome with NLRC4 & XIAP mutations, with AB2 Bio retaining US rights to all other indications & all rights outside the US
- AB2 Bio received a $6M option fee in 2025 & will now receive a $30M option exercise payment, ~$100M in development milestones, ~$500M in commercial milestones & royalties, while continuing to lead BLA preparation & other US regulatory activities
- Tadekinig alfa is a recombinant human IL-18 binding protein (IL-18BP) that neutralizes excess free IL-18. AB2 Bio completed a P-III in its lead indication & demonstrated clinical PoC in 3 additional life-threatening orphan diseases
Ref: Globenewswire | Image: Nippon Shinyaku & AB2 Bio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
